Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification (original) (raw)
Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop
Charles Sawyers
Proceedings of the National Academy of Sciences, 2002
View PDFchevron_right
Resistance of Philadelphia-chromosome positive leukemia towards the kinase inhibitor imatinib (STI571, Glivec): a targeted oncoprotein strikes back
Nikolas von Bubnoff
Leukemia, 2003
View PDFchevron_right
Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy
Manuela Mancini
Molecular Cancer, 2018
View PDFchevron_right
Bcr-Abl Kinase Domain Mutations and the Unsettled Problem of Bcr-AblT315I: Looking into the Future of Controlling Drug Resistance in Chronic Myeloid Leukemia
Christopher Eide
Clinical Lymphoma and Myeloma, 2007
View PDFchevron_right
BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571
moshe joanthan
…, 2003
View PDFchevron_right
Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors
Guillermo García
2007
View PDFchevron_right
The BCR-ABL35INS insertion/truncation mutant is kinase-inactive and does not contribute to tyrosine kinase inhibitor resistance in chronic myeloid leukemia
Christopher Eide
Blood, 2011
View PDFchevron_right
Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency
Timothy Hughes
Journal of Clinical Investigation, 2007
View PDFchevron_right
Case study of primary imatinib resistance and correlation of BCR-ABL multiple mutations in chronic myeloid leukemia
zafar iqbal
Therapy, 2004
View PDFchevron_right
Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells
Julian Topaly
Leukemia, 2001
View PDFchevron_right
Genetics and tyrosine kinase inhibitors of chronic myeloid leukemia
Nitin Kadam
The Nucleus, 2019
View PDFchevron_right
A cell-based screen for resistance of Bcr-Abl-positive leukemia identifies the mutation pattern for PD166326, an alternative Abl kinase inhibitor
Nikolas von Bubnoff, William Bornmann
Blood, 2005
View PDFchevron_right
Frequency of ABL gene mutations in chronic myeloid leukemia patients resistant to imatinib and results of treatment switch to second-generation tyrosine kinase inhibitors
Concha Boque
Medicina Clínica, 2013
View PDFchevron_right
Resistance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia—From Molecular Mechanisms to Clinical Relevance
Ana Cristina Gonçalves
Cancers
View PDFchevron_right
Coexisting with clonal evolution and BCR-ABL mutant in CML patients treated with second-generation tyrosine kinase inhibitors predict the discrepancy of in vitro drug sensitivity
Hyeoung-Joon Kim
Cancer research and treatment : official journal of Korean Cancer Association, 2010
View PDFchevron_right
Tyrosine kinase inhibitor AG1024 exerts antileukaemic effects on STI571-resistant Bcr-Abl expressing cells and decreases AKT phosphorylation
Ali Turhan
British journal of cancer, 2004
View PDFchevron_right
Analysis of the Structural Basis of Specificity of Inhibition of the Abl Kinase by STI571
Pascal Furet
Journal of Biological Chemistry, 2002
View PDFchevron_right
chronic myeloid leukemia Bcr-Abl kinase domain mutations, drug resistance and the road to a cure of
christophe Eid
2010
View PDFchevron_right
Analysis of BCR–ABL1 tyrosine kinase domain mutational spectra in primitive chronic myeloid leukemia cells suggests a unique mutator phenotype
Martin Dyer
Leukemia, 2010
View PDFchevron_right
Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: An Evolving Paradigm of Molecularly Targeted Therapy
Mohamed Ali
Molecular diagnosis & therapy, 2016
View PDFchevron_right
Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia
Christopher Eide
Blood, 2007
View PDFchevron_right
Chronic Myeloid Leukemia: The Mutational Landscape
Rabia Butt
2015
View PDFchevron_right
BCR-ABL Tyrosine Kinase Activity Regulates the Expression of Multiple Genes Implicated in the Pathogenesis of Chronic Myeloid Leukemia1
sara vieira
View PDFchevron_right
Aberrant Proliferative and Apoptotic Pathways in Acute Lymphoblastic Leukemia (ALL): Molecular Therapies to Overcome Chemo-Resistance
Fabiana Cave
Novel Aspects in Acute Lymphoblastic Leukemia, 2011
View PDFchevron_right
Resistance to Targeted Therapy in Chronic Myelogenous Leukemia
Philipp Erben
Seminars in Hematology, 2007
View PDFchevron_right
Emerging Strategies for the Treatment of Mutant Bcr-Abl T315I Myeloid Leukemia
Tariq Mughal
Clinical Lymphoma and Myeloma, 2007
View PDFchevron_right
BCR-ABL TARGETED THERAPIES ASSOCIATED WITH LEUKEMIA CHRONIC MYELOID (Atena Editora)
Atena Editora
BCR-ABL TARGETED THERAPIES ASSOCIATED WITH LEUKEMIA CHRONIC MYELOID (Atena Editora), 2024
View PDFchevron_right